

Saskatchewan Immunization Manual Amendments September 2023

Notice: As of September 1, 2023, an 'all pages' amendments document is no longer produced. Immunizers can print vaccine amendment pages from the [online SIM](#) at their convenience.

Chapter 9 Management of Biological Products

- Pp. 27-28 Section 5.2 Cold Chain Break Report form and separate link updated
- P. 29 Section 5.2A How to complete a CCB report form – Instructions updated.
- P. 30 – Section 5.3 Product Wastage report form and separate link updated for Moderna XBB.1.5. **However, continue to report BA.4/5 wastages as 10 doses per vial.**
- P. 32 Section 5.4 Vaccine Returns form and separate link updated
- Pp. 35-36 Section 5.6 Vaccine Supply Problem Report form – Most current version Dec. 2021 added.

Chapter 10 Biological Products

- TOC third page
 - **New!** AREXVY RSV vaccine for 60+ years added as a non-publicly funded vaccine.
- Infanrix-IPV/Hib and Pediacel (DTaP-IPV-Hib)
 - Both vaccines are now 2 pages.
 - Additions to Contraindications as noted on fact sheets and product monographs:
 - Individuals who have experienced transient thrombocytopenia or other neurological complications following an earlier immunization against diphtheria and/or tetanus.
 - Pertussis-containing vaccine should not be administered to persons with uncontrolled neurologic disorders (such as epilepsy) or to those who had a neurological event within 7 days of a getting a previous dose of a pertussis-containing vaccine that is not attributable to another identifiable cause.
- Novavax NUVAXOVID
 - Update product monograph
 - Added under Precautions: Myocarditis was identified in two teenage men shortly after receiving a second dose of vaccine resulting in a mild clinical course with complete resolution and no sequelae. Currently available information is insufficient to determine a causal relationship with NUVAXOVID.
 - Under Storage and Handling – After first puncture, vaccine is stable for 6 hours at room temperature (up to +25C).
- Gardasil 9 (HPV-9)
 - Gender at birth added to indications.
 - 2- dose schedule policy revision: Persons who received their first HPV dose before their 15th birthday **must** complete the 3-dose schedule if they present for their second dose after their 15th birthday.
- Non-public funded influenza vaccines – general manufacturer links updated.
- Publicly Funded Influenza vaccine pages -
 - Afluria Tetra updated as per 2023-24 product monograph
 - FluLaval Tetra - general manufacturer link updated.
 - FluZone Quadrivalent - general manufacturer link updated.
 - FluZone High-Dose Quadrivalent - general manufacturer link updated.
- IMVAMUNE
 - Updated under Other Considerations: IMVAMUNE is a non-replicating live vaccine and it can be co-administered with or given any time before or after another live vaccine, an immune globulin product or tuberculin skin testing.

Saskatchewan Immunization Manual Amendments

September 2023

- ProQuad and Priorix-Tetra
 - Expected reactions aligned with 2023 MMRV fact sheet.

Local: Pain, redness and swelling.

Systemic:

- A fever lasting up to 3 days may occur 7 to 10 days after getting this vaccine. Monitor your child and treat their fever (at least 6 to 8 hours after immunization) **if** they are uncomfortable, refusing fluids and not sleeping.
- Less than 1 in 3,000 children with high fevers after getting their first dose of MMRV **may** have a febrile seizure. **Febrile seizures are temporary and not harmful to the child. If you are concerned, please talk to a public health nurse.**
- Swelling of the jawline (salivary glands), cheeks and neck 7 to 12 days later.
- Joint or muscle aches and pain.
- Nausea, vomiting, diarrhea or decreased appetite.
- Headache, dizziness, fussiness, tiredness.
- Lymph nodes swelling near the immunized limb.
- A blotchy red rash 4 to 12 days later.
- A varicella-like (blister) rash 5 to 26 days after getting immunized. People who have this rash rarely spread the vaccine virus to others. To prevent possible viral spreading, the rash should be covered until the blisters have dried and crusted over.

Extremely rare reactions may include:

- A temporary drop of the number of blood cells (platelets) that prevent bleeding (thrombocytopenia) within 6 weeks of being immunized. In most people, this resolves within 3 months without serious complications.
- Encephalitis (less than one in one million). The risk of encephalitis from measles disease is about one in 1,000, which is much higher than from this vaccine.

- Adacel and Boostrix (Tdap)
 - Each vaccine is now 2 pages.
 - Additional contraindications added as noted in CIG and the product monographs to align with the updated fact sheets.
 - People who developed encephalopathy (e.g., coma, decreased level of consciousness, prolonged seizures) within 7 days of a previous dose of a pertussis-containing vaccine that is not attributable to another identifiable cause.
 - People with a progressive neurologic disorder, including infantile spasms, uncontrolled epilepsy or progressive encephalopathy. Pertussis-containing vaccine should not be administered to persons with such conditions until a treatment regimen has been established and the condition has stabilized.
 - Individuals who have experienced transient thrombocytopenia or other neurological complications following an earlier immunization against diphtheria and/or tetanus.
- Adacel-Polio and Boostrix-Polio (Tdap-IPV)
 - Additions to Contraindications as noted on fact sheets and product monographs:
 - Individuals who have experienced transient thrombocytopenia or other neurological complications following an earlier immunization against diphtheria and/or tetanus.
 - Pertussis-containing vaccine should not be administered to persons with uncontrolled neurologic disorders (such as epilepsy) or to those who had a neurological event within 7 days of a getting a previous dose of a pertussis-containing vaccine that is not attributable to another identifiable cause.
- Other product monograph or link updates:
 DUKORAL RECOMBIVAX HB MMRII PRIORIX PRIORIX-TETRA (link only)
 MENJUGATE Liquid (link only) NeisVac-C (link only) Menactra (link only) Menveo (link only)
 Bexsero (link only) Trumenba (link only) SYNFLORIX (link only) Pevnar 13 (link only)
 VAXNEUVANCE (link only) Pevnar 20 (link only) Pneumovax 23 (link only) IMOVAX Polio (link only) AREXVY (New!) BOOSTRIX (link only) VARILRIX (link only) HperHEP B (new link)
 GamaSTAN (link only) BAT

Saskatchewan Immunization Manual Amendments
September 2023

Chapter 14 Appendices

p. 21 – English fact sheet **dates updated as applicable.**